Never miss a story

Get subscribed to our newsletter


×
Diabetes is the ninth leading cause of death in women and claims 2.1 million female lives every year, more so than men. Pixabay

Researchers, including one of an Indian-origin, have shed light on how a class of medications that help regulate blood sugar for patients with Type 2 diabetes can also protect from heart disease.

The findings published in the journal Cell Metabolism, focus on the effect of diabetes medication — empagliflozin — on cell repair in blood vessels and the resulting risks of heart disease.


Empagliflozin is a medication that falls under a category of drugs called SGLT2 inhibitors, which lower blood sugar.

“We have seen large-scale clinical trials giving us clear evidence that SGLT2 inhibitors can also protect our patients who have diabetes from heart disease,” said Indian-origin researcher and study author Subodh Verma from St. Michael’s Hospital in Canada.

The research suggests that circulating progenitor cells — which are found in the bone marrow and play a role in heart health — along with inflammatory cells are regulated with this diabetes medication.

For patients who have diabetes are at the risk of heart disease, such medications may provide heart protection by relieving damaged cells that would otherwise perpetuate heart disease by causing faulty vessel repair.


According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes. Pixabay

Using blood samples from the EMPA-HEART CardioLink-6 Trial, the research team was able to show that in diabetes, regenerative progenitor cells were reduced.

Patients who took empagliflozin, however, these progenitor cells were restored later.

“We found that in people with diabetes, not only were beneficial progenitor cells increased but we saw indications of reduced inflammation and oxidative stress, which can also contribute to cardiovascular disease,” said David Hess, Associate Professor at Western University.

According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes.

Also Read: Social Networking Giant Facebook Plans Test to Let Users Hide ‘Like’ Counts

Earlier a research from Karolinska Institute in Sweden said that the new type of drugs for type 2 diabetes — SGLT2 inhibitors — are associated with a reduced risk of heart failure by 34 per cent.

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period. (IANS)


Popular

The New Indian Express/wikipedia

Named SEE-1, the module is intended to host films, etc in the low orbit, micro-gravity environment.

S.E.E. has unveiled plans to build a space station module that contains a sports and entertainment arena as well as a content studio by December 2024, reports variety.com.

Named SEE-1, the module is intended to host films, television, music and sports events as well as artists, producers and creatives who want to make content in the low orbit, micro-gravity environment. The facilities will enable development, production, recording, broadcasting and livestreaming of content.

Also read: Kings Of Leon Become First Band To Have NFT

S.E.E. intend to produce its own content and events in the module as well as making it available to third-parties. Axiom Space, who in January 2022 won NASA's approval to build a commercial component of the International Space Station (ISS), will undertake the construction of SEE-1. The module will dock on Axiom's commercial arm, named Axiom Station, which will also host other commercial ventures, including space tourism.

Keep Reading Show less
IANS

As the economy continues to recover from the prolonged pandemic.

By Rohit Vaid
The Centre might bestow infrastructure as well as industry status to new sectors to boost several pandemic hit industries in the upcoming Union Budget. Industry insiders said that several sectors and sub-industries such as hospitality, automobile retail, specific diganotics facilities and companies engaged in installation of EV charging stations amongst others might get the status.
The infra tag will enable these sectors to avail tax breaks, incentives and credit on lower interest rates. "Sectors which are in greenfield or which would need capex augmentation to help them overcome the pandemic can be looked from the lens of an infrastructure sector," said Jagannarayan Padmanabhan, Director and Practice Leader, Transport & Logistics, Crisil Infrastructure Advisory. "Also many of the already identified sectors need a sustained policy push which will help them get visibility both in terms of quantum and the time period of applicability."

Till now, activities associated with laying of power and telecom transmission and distribution lines, roads, highways, railways and construction of facilities such as hospitals, affordable housing, power generation units, water treatment plants, SEZs and certain type of hotels amongst others were given such status.

Besides, these sectors are a part of harmonised master list for infrastructure sub-sectors. However, in April 2021, exhibition-cum-convention centre was included in the list. "Given the focus around electric vehicle, and need for significant investment in charging stations, if the government adds the sector in infrastructure list, the benefits arising out of it will be significant," said Vishal Kotecha, Director, India Ratings and Research. "Infra tag on sectors increases ability to raise funds, access to dedicated funds and lenders, foreign capital, lower interest rates among others."

Electric car Given the focus on electric vehicles, the advantages of including the industry in the infrastructure list will be enormous. Free SVG

Keep Reading Show less
Wikipedia

A team is working to produce safest medicine for covid treatment.

A team led by chief scientist Ravi Shankar, is working on two combinations to provide the safest medication to coronavirus patients. "Experts say that a combination of antivirals with different mechanisms can be more effective to counter the viral pandemic. We are working on two combinations - Umifenovir with Molnupiravir (an antiviral) and Umifenovir with Niclosamide (anti-parasitic)," he said.

Also read: Antiviral Remdesivir Receives FDA

Molnupiravur drug has received only Emergency Use Authorisation in India and abroad. Though its usage showed reduced hospitalisation during clinical trials, its biggest drawback are the side-effects, he added.

"Now, we are trying to keep a low dosage of Molnupiravir in its combination with Umifenovir which may weed out the side-effects such as the risk of cartilage and muscle damage. If successful, it will make Umifenovir more effective in Covid-19 treatment," said the chief scientist. The other combination is Umifenovir with Niclosamide.

Keep reading... Show less